Telix Historical Balance Sheet

TLX Stock

15.76 0.16 1.03%

Trend analysis of Telix Pharmaceuticals Limited balance sheet accounts such as Total Stockholder Equity of 85.3 M, Property Plant And Equipment Net of 16.6 M, Current Deferred Revenue of 117.6 M or Accounts Payable of 18.5 M provides information on Telix Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Telix Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Telix Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Telix Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Telix Pharmaceuticals is a good buy for the upcoming year.

Telix Pharmaceuticals Inventory

18.18 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Telix Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Telix Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Telix Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Telix Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Telix currently owns. An asset can also be divided into two categories, current and non-current.

Telix Pharmaceuticals Balance Sheet Chart

At this time, Telix Pharmaceuticals' Other Current Liabilities is fairly stable compared to the past year. Current Deferred Revenue is likely to rise to about 117.6 M in 2024, whereas Total Assets are likely to drop slightly above 253.4 M in 2024.

Short Long Term Debt Total Other Current Liab Total Current Liabilities Good Will Total Current Assets

Total Current Liabilities

Total Current Liabilities is an item on Telix Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Telix Pharmaceuticals Limited are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Good Will

An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most accounts from Telix Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	2.5M	10.4M	17.4M	9.0M
Total Assets	109.8M	255.4M	398.3M	253.4M

Short Long Term Debt Total Total Assets

Telix Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		0.98	0.81	0.96	0.78	0.97	0.87	-0.74	-0.78	0.93	0.82	0.96	0.97	0.86	0.82	0.95	0.73	0.85	0.85	0.92	0.86	0.88	0.94	0.81	0.96	0.9
Short Long Term Debt Total	0.98		0.79	0.99	0.62	1.0	0.91	-0.64	-0.88	0.98	0.72	0.94	0.99	0.93	0.72	0.99	0.79	0.9	0.93	0.98	0.9	0.89	0.99	0.67	1.0	0.9
Other Current Liab	0.81	0.79		0.82	0.54	0.8	0.92	-0.58	-0.74	0.83	0.5	0.87	0.85	0.82	0.5	0.81	0.57	0.85	0.74	0.73	0.94	0.96	0.81	0.58	0.8	0.83
Total Current Liabilities	0.96	0.99	0.82		0.56	1.0	0.92	-0.56	-0.89	0.99	0.65	0.95	0.99	0.97	0.65	1.0	0.75	0.9	0.94	0.97	0.92	0.9	1.0	0.61	1.0	0.88
Total Stockholder Equity	0.78	0.62	0.54	0.56		0.6	0.47	-0.82	-0.25	0.5	0.89	0.7	0.62	0.37	0.89	0.55	0.37	0.43	0.34	0.5	0.45	0.54	0.51	1.0	0.58	0.61
Property Plant And Equipment Net	0.97	1.0	0.8	1.0	0.6		0.92	-0.62	-0.89	0.98	0.7	0.94	0.99	0.94	0.7	1.0	0.79	0.91	0.94	0.98	0.91	0.9	0.99	0.64	1.0	0.9
Current Deferred Revenue	0.87	0.91	0.92	0.92	0.47	0.92		-0.64	-0.94	0.92	0.59	0.86	0.91	0.9	0.59	0.93	0.82	0.99	0.93	0.91	1.0	0.99	0.93	0.52	0.92	0.95
Net Debt	-0.74	-0.64	-0.58	-0.56	-0.82	-0.62	-0.64		0.5	-0.49	-0.95	-0.57	-0.58	-0.37	-0.95	-0.57	-0.74	-0.67	-0.54	-0.63	-0.61	-0.68	-0.57	-0.82	-0.61	-0.83
Retained Earnings	-0.78	-0.88	-0.74	-0.89	-0.25	-0.89	-0.94	0.5		-0.89	-0.49	-0.74	-0.85	-0.89	-0.49	-0.9	-0.9	-0.97	-0.99	-0.94	-0.93	-0.88	-0.92	-0.3	-0.9	-0.89
Accounts Payable	0.93	0.98	0.83	0.99	0.5	0.98	0.92	-0.49	-0.89		0.56	0.95	0.99	0.99	0.56	0.99	0.7	0.89	0.93	0.94	0.92	0.9	0.99	0.55	0.98	0.84
Cash	0.82	0.72	0.5	0.65	0.89	0.7	0.59	-0.95	-0.49	0.56		0.65	0.66	0.44	1.0	0.65	0.71	0.62	0.57	0.7	0.55	0.62	0.63	0.89	0.69	0.79
Non Current Assets Total	0.96	0.94	0.87	0.95	0.7	0.94	0.86	-0.57	-0.74	0.95	0.65		0.98	0.91	0.65	0.94	0.58	0.8	0.8	0.86	0.87	0.88	0.93	0.74	0.94	0.81
Non Currrent Assets Other	0.97	0.99	0.85	0.99	0.62	0.99	0.91	-0.58	-0.85	0.99	0.66	0.98		0.96	0.66	0.99	0.7	0.88	0.9	0.94	0.91	0.91	0.98	0.66	0.99	0.87
Long Term Debt	0.86	0.93	0.82	0.97	0.37	0.94	0.9	-0.37	-0.89	0.99	0.44	0.91	0.96		0.44	0.97	0.66	0.87	0.92	0.91	0.91	0.87	0.97	0.43	0.95	0.78
Cash And Short Term Investments	0.82	0.72	0.5	0.65	0.89	0.7	0.59	-0.95	-0.49	0.56	1.0	0.65	0.66	0.44		0.65	0.71	0.62	0.57	0.7	0.55	0.62	0.63	0.89	0.69	0.79
Net Receivables	0.95	0.99	0.81	1.0	0.55	1.0	0.93	-0.57	-0.9	0.99	0.65	0.94	0.99	0.97	0.65		0.77	0.91	0.95	0.98	0.92	0.9	1.0	0.6	1.0	0.89
Good Will	0.73	0.79	0.57	0.75	0.37	0.79	0.82	-0.74	-0.9	0.7	0.71	0.58	0.7	0.66	0.71	0.77		0.9	0.9	0.88	0.79	0.77	0.8	0.41	0.79	0.92
Common Stock Shares Outstanding	0.85	0.9	0.85	0.9	0.43	0.91	0.99	-0.67	-0.97	0.89	0.62	0.8	0.88	0.87	0.62	0.91	0.9		0.96	0.93	0.98	0.96	0.92	0.47	0.91	0.97
Non Current Liabilities Total	0.85	0.93	0.74	0.94	0.34	0.94	0.93	-0.54	-0.99	0.93	0.57	0.8	0.9	0.92	0.57	0.95	0.9	0.96		0.98	0.92	0.88	0.96	0.39	0.95	0.9
Capital Lease Obligations	0.92	0.98	0.73	0.97	0.5	0.98	0.91	-0.63	-0.94	0.94	0.7	0.86	0.94	0.91	0.7	0.98	0.88	0.93	0.98		0.9	0.87	0.98	0.55	0.98	0.92
Inventory	0.86	0.9	0.94	0.92	0.45	0.91	1.0	-0.61	-0.93	0.92	0.55	0.87	0.91	0.91	0.55	0.92	0.79	0.98	0.92	0.9		0.99	0.93	0.49	0.91	0.93
Other Current Assets	0.88	0.89	0.96	0.9	0.54	0.9	0.99	-0.68	-0.88	0.9	0.62	0.88	0.91	0.87	0.62	0.9	0.77	0.96	0.88	0.87	0.99		0.91	0.58	0.9	0.94
Total Liab	0.94	0.99	0.81	1.0	0.51	0.99	0.93	-0.57	-0.92	0.99	0.63	0.93	0.98	0.97	0.63	1.0	0.8	0.92	0.96	0.98	0.93	0.91		0.56	1.0	0.89
Net Invested Capital	0.81	0.67	0.58	0.61	1.0	0.64	0.52	-0.82	-0.3	0.55	0.89	0.74	0.66	0.43	0.89	0.6	0.41	0.47	0.39	0.55	0.49	0.58	0.56		0.63	0.65
Property Plant And Equipment Gross	0.96	1.0	0.8	1.0	0.58	1.0	0.92	-0.61	-0.9	0.98	0.69	0.94	0.99	0.95	0.69	1.0	0.79	0.91	0.95	0.98	0.91	0.9	1.0	0.63		0.9
Short Long Term Debt	0.9	0.9	0.83	0.88	0.61	0.9	0.95	-0.83	-0.89	0.84	0.79	0.81	0.87	0.78	0.79	0.89	0.92	0.97	0.9	0.92	0.93	0.94	0.89	0.65	0.9

Click cells to compare fundamentals

Telix Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Telix Historical Balance Sheet

Telix Pharmaceuticals Inventory

18.18 Million

About Telix Balance Sheet Analysis

Telix Pharmaceuticals Balance Sheet Chart

Total Current Liabilities

Good Will

Total Current Assets

Telix Pharmaceuticals balance sheet Correlations

Telix Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Telix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Net	+ 1.0	Total Current Liabilities
Net Receivables	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Property Plant And Equipment Gross	+ 1.0	Total Current Liabilities

Non Current Liabilities Total	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt
Capital Lease Obligations	- 0.94	Retained Earnings
Retained Earnings	- 0.94	Current Deferred Revenue